ArticleJournal of clinical immunology2007
Correction of Th1-dominant cytokine profiles by high-dose dexamethasone in patients with chronic idiopathic thrombocytopenic purpura.
Article in Journal of clinical immunology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 96 citations in OpenAlex.
- Downregulation of T-bet/GATA-3 ratio induced by IL-11 treatment is responsible for Th1/Th2 balance restoration in human immune thrombocytopenic purpura (ITP).Journal of thrombosis and thrombolysis · 2014Trial
- Echinococcus granulosus antigen B regulates T-cell function through inhibition of signal transducer and activator of transcription 3 in experimental immune thrombocytopenia.British journal of haematology · 2025Article
- The function of T cells in immune thrombocytopenia.Frontiers in immunology · 2025Review
- Causal Relationship between Helicobacter Pylori Antibodies and Immune Thrombocytopenia: A Mendelian Randomization Study.Mediterranean journal of hematology and infectious diseases · 2025Article
- Therapeutic Outcomes of High Dose-Dexamethasone versus Prednisolone + Azathioprine, Rituximab, Eltrombopag, and Romiplostim Strategies in Persistent, Chronic, Refractory, and Relapsed Immune Thrombocytopenia Patients.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Role of IL-10 and IL-22 cytokines in patients with primary immune thrombocytopenia and their clinical significance.Journal of clinical laboratory analysis · 2022Article
- Low-dose decitabine modulates T-cell homeostasis and restores immune tolerance in immune thrombocytopenia.Blood · 2021Article
- Idiopathic thrombocytopenic purpura as a hematologic manifestation of COVID-19 infection: A case report.Respiratory medicine case reports · 2021Article
- Rituximab in the treatment of immune thrombocytopenia: what is the role of this agent in 2019?Haematologica · 2019Review
- High-Dose Dexamethasone Alters the Increase in Interleukin-16 Level in Adult Immune Thrombocytopenia.Frontiers in immunology · 2019Article
- Assessment of soluble cytotoxic T lymphocyte-associated antigen-4, transforming growth factor βJournal of blood medicine · 2019Article
- Imbalanced immune homeostasis in immune thrombocytopenia.Seminars in hematology · 2016Article
- Cytokines and Effector/Regulatory Cells Characterization in the Physiopathology of Cutaneous Lupus Erythematous: A Cross-Sectional Study.Mediators of inflammation · 2016Article
- Pathogenesis-oriented approaches for the management of corticosteroid-resistant or relapsedprimary immune thrombocytopenia.Open medicine (Warsaw, Poland) · 2016Article
- Plasma Levels of Interleukin 12 Family Cytokines and Their Relevant Cytokines in Adult Patients with Chronic Immune Thrombocytopenia before and after High-Dose Dexamethasome Treatment.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2015Article
- Article
- T cell immune abnormalities in immune thrombocytopenia.Journal of hematology & oncology · 2014Review
- Immunoregulation therapy changes the frequency of interleukin (IL)-22+ CD4+ T cells in systemic lupus erythematosus patients.Clinical and experimental immunology · 2014Article
- Advances in immunopathogenesis of adult immune thrombocytopenia.Frontiers of medicine · 2013Review
- Characterization of Th1- and Th2-associated chemokine receptor expression in spleens of patients with immune thrombocytopenia.Journal of clinical immunology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To investigate the possible correcting of T helper (Th) cytokine profiles by high-dose dexamethasone (HD-DXM) therapy in chronic idiopathic thrombocytopenic purpura (ITP) with active disease, we determined the plasma levels of IFN-gamma, IL-2, IL-4, IL-10, and TGF-beta1 in 52 patients before and after oral administration of 40 mg/day DXM for four consecutive days. The cytokine levels were measured by enzyme-linked immunosorbent assay. The results showed that initial responses were reached in all patients and sustained response (SR) rate is 46.15%. The pretreatment plasma levels of both IFN-gamma and IL-2 were significantly increased and those of IL-4, IL-10, and TGF-beta1 significantly decreased, compared with those of the normal controls (P < 0.01), indicating a Th1-dominant cytokine profile typically found in ITP. After HD-DXM treatment, IFN-gamma and IL-2 were decreased (P < 0.01), whereas IL-4 and IL-10 were increased (P < 0.05). There was no significant difference between the HD-DXM-treated patients and the normal controls (P > 0.05). TGF-beta1 was also increased (P < 0.01) after HD-DXM treatment, but still lower than that of the normal controls (P < 0.05). During following-up, the cytokine profiles in the SRs remained stable compared to the posttreatment level (P > 0.05), but IFN-gamma and IL-2 levels raised up, and IL-4, IL-10, and TGF-beta1 levels reduced again in the relapsed patients (P < 0.01). Our data demonstrate that HD-DXM is an effective initial therapy for ITP, and the Th1 cytokine dominance could be corrected by HD-DXM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.